Phase 2 Head and Neck Cancer Trial, Recruiting NCT07085988 Sponsor: Jiangxi Provincial Cancer Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT07085988
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) confirmed by a laboratory tissue test
  • People whose cancer is at a stage classified as Stage II, III, or IVa, and whose treatment plan includes receiving chemotherapy and radiation therapy at the same time
  • People aged 18 or older, of any gender
  • People whose nutritional status, measured by a specific scoring tool called the PG-SGA, falls between 0 and 8 before radiation treatment begins
  • People whose general physical ability and health status meets a minimum level, as measured by standard medical scoring tools (confirm with trial site)
  • People who are able to take nutritional supplements by mouth or through a feeding tube
  • People who are willing to sign a formal consent form agreeing to take part in the study
  • People whose blood test results show healthy enough levels of red blood cells, platelets, and white blood cells before starting the trial
  • People whose kidney function blood test results are within an acceptable range
  • People whose liver function blood test results are within an acceptable range

Who may not be able to join:

  • People who have a second, separate cancer diagnosis at the same time
  • People who are not receiving chemotherapy and radiation therapy together as part of their treatment
  • People who have diabetes, or who have a history of serious hormone or metabolism-related conditions
  • People who are allergic to oral nutritional meal replacement products

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: CHINA/360100+13699526170

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jiangxi Provincial Cancer Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Decreased proportion of immune cell subsets

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov